Enanta Pharmaceuticals, Inc.

The momentum for this stock is not very good. Enanta Pharmaceuticals, Inc. is not very popular among insiders. Enanta Pharmaceuticals, Inc. is a mediocre stock to choose.
Log in to see more information.
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. It engages...
ENTA Fundamental Data by TradingView

News

Acadian Asset Management LLC Has $11.01 Million Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
Acadian Asset Management LLC Has $11.01 Million Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Ticker Report Acadian Asset Management LLC lessened its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 0.5% in the second quarter, according to the company in its most recent...\n more…

Insiders Relieved After Selling Enanta Pharmaceuticals With 10% Price Dip
Insiders Relieved After Selling Enanta Pharmaceuticals With 10% Price Dip

Simply Wall St Over the past year, insiders sold US$325k worth of Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) stock at an average...\n more…

Enanta Pharmaceuticals to Participate in Investor Conferences in September
Enanta Pharmaceuticals to Participate in Investor Conferences in September

Business Wire Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of...\n more…

Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $19.00
Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $19.00

Zolmax Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six ratings firms that are currently covering the company, MarketBeat...\n more…

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Ticker Report Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are presently covering the stock, MarketBeat.com reports...\n more…

Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Below Two Hundred Day Moving Average of $13.75
Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Below Two Hundred Day Moving Average of $13.75

Zolmax Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of...\n more…